Renal denervation in heart failure with normal left ventricular ejection fraction. rationale and design of the diastole (denervation of the renal sympathetic nerves in heart failure with normal lv ejection fraction) trial

European Journal of Heart Failure

Volumn 15, Issue 12, 2013, Pages 1429-1437

  Verloop, Willemien L ^a   Beeftink, Martine M A ^a   Nap, Alex ^b   Bots, Michiel L ^a   Velthuis, Birgitta K ^a   Appelman, Yolande E ^b   Cramer, Maarten Jan ^a   Agema, Willem R P ^c   Scholtens, Asbjorn M ^a   Doevendans, Pieter A ^a   Allaart, Cor P ^b   Voskuil, Michiel ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

Heart failure with normal LV ejection fraction; Heart failure with preserved LV ejection fraction; Hypertension; Renal denervation

Indexed keywords

(3 IODOBENZYL)GUANIDINE; BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIASTOLIC HEART FAILURE; DOPPLER ECHOCARDIOGRAPHY; EXERCISE; FEMALE; HEART FAILURE WITH NORMAL LEFT VENTRICULAR EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE VARIABILITY; HUMAN; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAFETY; SYMPATHETIC INNERVATION;

HEART FAILURE WITH NORMAL LV EJECTION FRACTION; HEART FAILURE WITH PRESERVED LV EJECTION FRACTION; HYPERTENSION; RENAL DENERVATION;

ECHOCARDIOGRAPHY, DOPPLER, PULSED; FEMALE; HEART FAILURE; HUMANS; KIDNEY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; STROKE VOLUME; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84890028987     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hft119     Document Type: Article

References (50)

1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93: 1137-1146.
2. Edelmann F, Schmidt AG, Gelbrich G, Binder L, Herrmann-Lingen C, Halle M, Hasenfuss G,Wachter R, Pieske B. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebocontrolled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur J Heart Fail 2010;12:874-882.
3. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-269.
4. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part 1: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002;105:1387-1393.
5. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-869.
6. Wachter R, Schmidt-Schweda S, Westermann D, Post H, Edelmann F, Kasner M, Luers C, Steendijk P, Hasenfuss G, Tschope C, Pieske B. Blunted frequencydependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure. Eur Heart J 2009;30:3027-3036.
7. SchlaichMP, Sobotka PA, Krum H, Whitbourn R,Walton A, EslerMD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009;54:1195-1201.
8. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, Del BA, Sala C, Bolla GB, Pozzi M. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995;92:3206-3211.
9. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-621.
10. Kaye DM, LambertGW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 1994; 23:570-578.
11. Sobotka PA, Krum H, Bohm M, Francis DP, Schlaich MP. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep 2012;14:285-292.
12. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 1997;95:169-175.
13. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-254.
14. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS, Esler MD. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996;93:1667-1676.
15. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Arenare F, Spaziani D, Mancia G. Sympathetic and baroreflex cardiovascular control in hypertensionrelated left ventricular dysfunction. Hypertension 2009;53:205-209.
16. Somsen GA, Dubois EA, Brandsma K, De Jong J, Van DerWouw PA, Batink HD, Van RoyenEA, Lie KI, Van Zwieten PA.Cardiac sympathetic neuronal function in left ventricular volume and pressure overload. Cardiovasc Res 1996;31:132-138.
17. Piccirillo G, Germano G, Vitarelli A, Ragazzo M, di Carlo S, De LaurentisT, Torrini A, Matera S, Magnanti M, Marchitto N, Bonanni L, Magri D. Autonomic cardiovascular control and diastolic dysfunction in hypertensive subjects. Int J Cardiol 2006;110: 160-166.
18. van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009;53:2150-2158.
19. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013;61:457-464.
20. Verloop WL, Voskuil M, Doevendans PA. Renal denervation: a new treatment option in resistant arterial hypertension. Neth Heart J 2013;21:95-98.
21. Brandt MC, Reda S, Mahfoud F, Lenski M, Bohm M, Hoppe UC. Effects of renal mpathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol 2012;60:1956-1965.
22. Osranek M, Seward JB, Buschenreithner B, Bergler-Klein J, Heger M, Klaar U, Binder T, Maurer G, Zehetgruber M. Diastolic function assessment in clinical practice: the value of 2-dimensional echocardiography. Am Heart J 2007;154:130-136.
23. Shuai XX, Chen YY, Lu YX, Su GH,Wang YH, Zhao HL, Han J. Diagnosis of heart failure with preserved ejection fraction: which parameters and diagnostic strategies are more valuable? Eur J Heart Fail 2011;13:737-745.
24. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De KG, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28: 2539-2550.
25. Groenveld HF, Tijssen JG, Crijns HJ, Van den Berg MP, Hillege HL, Alings M, Van Veldhuisen DJ, Van Gelder IC RACE II Investigators. Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol 2013;61:741-748.
26. Arques S, Roux E, Sbragia P, Pieri B, Gelisse R, Luccioni R, Ambrosi P. Usefulness of bedside tissue Doppler echocardiography and B-type natriuretic peptide (BNP) in differentiating congestive heart failure from noncardiac cause of acute dyspnea in elderly patients with a normal left ventricular ejection fraction and permanent, nonvalvular atrial fibrillation: insights from a prospective, monocenter study. Echocardiography 2007;24:499-507.
27. Persson H, Lonn E, Edner M, Baruch L, Lang CC, Morton JJ, Ostergren J,McKelvie RS. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from theCHARMEchocardiographic Substudy-CHARMES. J Am Coll Cardiol 2007;49:687-694.
28. Galderisi M. Diastolic dysfunction and diastolic heart failure: diagnostic, prognostic and therapeutic aspects. Cardiovasc Ultrasound 2005;3:9.
29. Khouri SJ, Maly GT, Suh DD, Walsh TE. A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr 2004;17:290-297.
30. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130: 461-470.
31. Daneshvar D,Wei J, Tolstrup K,Thomson LE, Shufelt C, MerzCN.Diastolic dysfunction: improved understanding using emerging imaging techniques. Am Heart J 2010; 160:394-404.
32. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, Pennell DJ. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 2000;21:1387-1396.
33. Edelmann F, Stahrenberg R, Polzin F, Kockskamper A, Dungen HD, Duvinage A, Binder L, Kunde J, Scherer M, Gelbrich G, Hasenfuss G, Pieske B, Wachter R, Herrmann-Lingen C. Impaired physical quality of life in patients with diastolic dysfunction associates more strongly with neurohumoral activation than with echocardiographic parameters Quality of life in diastolic dysfunction. Am Heart J 2011;161: 797-804.
34. Grassi G, Bolla G, Quarti-Trevano F, Arenare F, Brambilla G, Mancia G. Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers. Eur J Heart Fail 2008;10:1186-1191.
35. Grewal J, McKelvie RS, Persson H, TaitP,Carlsson J, Swedberg K, Ostergren J, Lonn E. Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol 2008;102:733-737.
36. Mak GS, DeMaria A, Clopton P, Maisel AS. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings. Am Heart J 2004;148:895-902.
37. Katoh S, Shishido T, Kutsuzawa D, Arimoto T, Netsu S, Funayama A, Ishino M, Niizeki T, Nishiyama S, Takahashi H, Miyashita T, Miyamoto T, Nitobe J, Watanabe T, Kubota I. Iodine-123-metaiodobenzylguanidine imaging can predictfuture cardiac events in heart failure patients with preserved ejection fraction. Ann Nucl Med 2010;24:1-8.
38. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D,Weiland F, Chandna H, Narula J, ADMIRE-HF Investigators. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-2221.
39. Parisotto V, Lima EM, Silva JM, de Sousa MR, Ribeiro AL. Cardiac sympathetic dysautonomia in children with chronic kidney disease. J Nucl Cardiol 2008;15: 246-254.
40. Kosaka T, Nakagawa M, Ishida M, Iino K,Watanabe H, Hasegawa H, Ito H. Cardioprotective effect of an L/N-type calcium channel blocker in patients with hypertensive heart disease. J Cardiol 2009;54:262-272.
41. Daniel KR,Wells G, Stewart K, Moore B, KitzmanDW. Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest Heart Fail 2009;15:68-74.
42. Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, Yip T, Lau ST, Lau CP, Tang MO, Yu CM, Sanderson JE. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008;94:573-580.
43. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T, Marwick TH. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging 2011;4:1239-1249.
44. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009;361:932-934.
45. Mahfoud F, Luscher TF, Andersson B, Baumgartner I, Cifkova R, Dimario C, Doevendans P, Fagard R, Fajadet J, Komajda M, Lefevre T, Lotan C, Sievert H, Volpe M, Widimsky P, Wijns W, Williams B, Windecker S, Witkowski A, Zeller T, Bohm M. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013;in press.
46. Davies JE, Manisty CH, Petraco R, Barron AJ, Unsworth B, Mayet J, Hamady M, Hughes AD, Sever PS, Sobotka PA, Francis DP. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACHPilot study. Int J Cardiol 2013;162:189-192.
47. Mahadevan G, Dwivedi G, Williams L, Steeds RP, Frenneaux M. Epidemiology and diagnosis of heart failure with preserved left ventricular ejection fraction: rationale and design of the study. Eur J Heart Fail 2012;14:106-112.
48. De Boeck BW, Cramer MJ, Oh JK, van der Aa RP, JaarsmaW. Spectral pulsed tissue Doppler imaging in diastole: a tool to increase our insight in and assessment of diastolic relaxation of the left ventricle. Am Heart J 2003;146:411-419.
49. Zhao Q, Yu S, Huang H, TangY, Xiao J, Dai Z,Wang X, Huang C. Effects of renal sympathetic denervation on the development of atrial fibrillation substrates in dogs with pacing-induced heart failure. Int J Cardiol 2013;in press.
50. van Kraaij DJ, van Pol PE, RuitersAW, de Swart JB, Lips DJ, Lencer N,Doevendans PA. Diagnosing diastolic heart failure. Eur J Heart Fail 2002;4:419-430